You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson’s Disease (PADOVA): Rationale, Design, and Baseline Data
Prasinezumab is an investigational treatment for Parkinson’s Disease (PD). The PADOVA trial (NCT04777331) is a Phase 2b, multicentre, randomised, double-blind, placebo-controlled study evaluating the efficacy and safety/tolerability of prasinezumab in individuals with early-stage PD on stable symptomatic therapy. This poster focuses on the rationale, study design and baseline characteristics of the PADOVA study population.
Request medical material
Would you like to receive this poster via email to view later?